

ENPATH MEDICAL, INC.
Form SC TO-T/A
June 11, 2007

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

Amendment No. 3

(Rule 14d-100)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

ENPATH MEDICAL, INC.

(Name of subject company (Issuer))

GREATBATCH, INC.

GREATBATCH LTD.

CHESTNUT ACQUISITION CORPORATION

(Names of Filing Persons (Offerors))

Common Stock, \$0.01 par value per share
(Title of classes of securities)

29355Y105
(CUSIP number of common stock)

Timothy G. McEvoy, Esq.

Vice President, General Counsel & Secretary

Greatbatch, Inc

9645 Wehrle Drive

Clarence, New York 14031

Telephone: (716)-759-5600

(Name, address, and telephone number of person authorized to receive notices and communications on behalf of Filing Persons)

Copies to:

Robert B. Fleming, Jr., Esq.

Asher Gaffney, Esq.

John J. Zak, Esq.

Hodgson Russ LLP

Hodgson Russ LLP

1540 Broadway, 24th Floor

The Guaranty Building

New York, New York 10036

140 Pearl Street, Suite 100

Telephone: (212) 751-4300

Buffalo, New York 14202

Telephone: (716) 856-4000

CALCULATION OF FILING FEE

**Transaction Valuation(1)
\$94,793,240**

**Amount of Filing Fee(2)
\$2,911**

- (1) Estimated for purposes of calculating the filing fee only. The transaction valuation was calculated based on the offer to purchase all of the outstanding shares of common stock of Enpath Medical, Inc. at a purchase price equal to \$14.38 per share and assumes the purchase of 6,361,727 issued and outstanding shares and outstanding options and warrants with respect to 794,150 shares, in each case as of April 28, 2007.
- (2) The amount of filing fee, calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, is calculated by multiplying the transaction valuation by 0.0000307.
- x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Amount Previously Paid: \$2,911

Filing Party: Greatbatch, Inc., Greatbatch Ltd., Chestnut Acquisition Corporation

Form of Registration No.: Schedule TO

Date Filed: May 8, 2007

.. Check the box if the filing relates solely to preliminary communications made before the commencement of the tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:

x third party tender offer subject to Rule 14d-1

.. issuer tender offer subject to Rule 13e-4

Edgar Filing: ENPATH MEDICAL, INC. - Form SC TO-T/A

going private transaction subject to Rule 13e-3

amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer: x

This Amendment No. 3 to the Tender Offer Statement on Schedule TO (this Amendment), filed with the Securities and Exchange Commission (the SEC) on June 11, 2007, amends and supplements the Tender Offer Statement of Schedule TO filed on May 8, 2007 (the Schedule TO) and relates to the offer by Chestnut Acquisition Corporation, a Minnesota corporation (the Purchaser), which is a wholly-owned subsidiary of Greatbatch Ltd., a New York corporation (Limited), which is an indirect wholly-owned subsidiary of Greatbatch, Inc., a Delaware corporation (Parent). The Schedule TO relates to the offer by the Purchaser to purchase all outstanding shares of common stock, \$0.01 par value per share (the Shares), of Enpath Medical, Inc., a Minnesota corporation (the Company or Enpath), at a purchase price of \$14.38 per Share in cash, without interest thereon, less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated May 8, 2007 (the Offer to Purchase), and in the related Letter of Transmittal, copies of which are attached as Exhibits (a)(1)(i) and (a)(1)(ii) (which, together with any amendments or supplements thereto, collectively constitute the Offer). Capitalized terms used and not defined herein shall have the meanings assigned such terms in the Offer to Purchase.

The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated in this Amendment by reference to all of the applicable items in the Schedule TO, except that such information is hereby amended and supplemented to the extent specifically provided herein.

Items 8 and 11. Interest in Securities of the Subject Company; Additional Information.

Items 8 and 11 of the Schedule TO are hereby amended and supplemented by adding the following text thereto:

The subsequent offering period of the Offer expired at 12:00 Midnight, New York City time, on Friday, June 8, 2007. According to Mellon Investor Services LLC, the depository for the Offer, a total of 5,839,942 Shares were validly tendered in the initial and subsequent offering periods of the Offer, which represent approximately 90.9% of all outstanding Shares. The Purchaser has accepted all Shares that were validly tendered for payment pursuant to the terms of the Offer and payment for those Shares will be made promptly in accordance with the terms of the Offer.

On June 8, 2007, Greatbatch announced that it expects the closing of the second step merger of the Purchaser with and into Enpath will occur on Friday, June 15, 2007. In connection with the Merger, each outstanding Share not tendered in the Offer (other than Shares held by Parent, Limited or Purchaser, or Shares held by shareholders who exercise their dissenters' rights under Minnesota law) will be converted into the right to receive \$14.38 per Share in cash, without interest, less any required withholding taxes. Enpath will be the surviving corporation in the Merger and will become an indirect wholly-owned subsidiary of Parent.

Item 12. Exhibits.

Item 12 is hereby amended and supplemented by adding the following exhibit:

(a)(5)(v) Press Release issued by Parent on June 11, 2007.

After due inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 11, 2007

CHESTNUT ACQUISITION CORPORATION

By: /s/ Thomas J. Mazza
Name: Thomas J. Mazza
Title: President and Chief Financial Officer

GREATBATCH LTD.

By: /s/ Thomas J. Mazza
Name: Thomas J. Mazza
Title: Senior Vice President and Chief Financial Officer

GREATBATCH, INC.

By: /s/ Thomas J. Mazza
Name: Thomas J. Mazza
Title: Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

- (a)(1)(i) Offer to Purchase, dated May 8, 2007.*
- (a)(1)(ii) Form of Letter of Transmittal.*
- (a)(1)(iii) Form of Notice of Guaranteed Delivery.*
- (a)(1)(iv) Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
- (a)(1)(v) Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
- (a)(1)(vi) Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.*
- (a)(1)(vii) Form of Summary Advertisement as published on May 8, 2007 in The Wall Street Journal.*
- (a)(5)(i) Joint press release issued by Greatbatch and the Company on April 30, 2007 (incorporated by reference to exhibit 99.1 to the Current Report on Form 8-K filed by Greatbatch on April 30, 2007).*
- (a)(5)(ii) Investor Presentation Materials dated April 30, 2007 (incorporated by reference to exhibit 99.2 to the Current Report on Form 8-K filed by Greatbatch on April 30, 2007).*
- (a)(5)(iii) Joint Press Release issued by Parent and Enpath on May 30, 2007.*
- (a)(5)(iv) Press Release issued by Parent on June 6, 2007.*
- (a)(5)(v) Press Release issued by Parent on June 11, 2007.
- (d)(1) Agreement and Plan of Merger, dated as of April 28, 2007, among Limited, the Purchaser and the Company (incorporated by reference to exhibit 2.1 to the Current Report on Form 8-K filed by Greatbatch on April 30, 2007).*
- (d)(2) Tender and Support Agreement, dated as of April 28, 2007, among Limited, the Purchaser and each person party thereto (incorporated by reference to exhibit 2.2 to the Current Report on Form 8-K filed by Greatbatch on April 30, 2007).*
- (d)(3)(i) Confidentiality Agreement, dated March 15, 2007, between Greatbatch and the Company.*
- (d)(3)(ii) Letter Agreement, dated April 17, 2007, between Greatbatch and the Company.*

* Previously filed.
Filed herewith.